Rebecca Taub Madrigal Pharmaceuticals, Inc. (MDGL) insider trading activity

Rebecca Taub is Pres., R&D, and CMO of MADRIGAL PHARMACEUTICALS, INC.. Currently has a direct ownership of 461,044 shares of MDGL, which is worth approximately $151 Million. The most recent transaction as insider was on Mar 05, 2025, when has been sold 4,382 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 461K

0.45% 3M change

0.45% 12M change

Total Value Held $151 Million

Rebecca Taub Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2025	BUY Grant, award, or other acquisition	-	4,382 Added 0.94%	461,044 Common Stock
Jan 24 2025	SELL Open market or private sale	$217,235 $335.24 p/Share	648 Reduced 0.14%	456,662 Common Stock
Jan 17 2025	SELL Open market or private sale	$461,789 $273.41 p/Share	1,689 Reduced 0.37%	457,310 Common Stock
Apr 08 2024	SELL Open market or private sale	$658,750 $246.17 p/Share	2,676 Reduced 0.58%	458,999 Common Stock
Apr 08 2024	BUY Exercise of conversion of derivative security	$25,288 $9.45 p/Share	2,676 Added 0.58%	461,675 Common Stock
Apr 05 2024	SELL Open market or private sale	$6,680,107 $242.86 p/Share	27,506 Reduced 5.65%	458,999 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	$259,931 $9.45 p/Share	27,506 Added 5.35%	486,505 Common Stock
Apr 04 2024	SELL Open market or private sale	$4,532,296 $244.5 p/Share	18,537 Reduced 3.88%	458,999 Common Stock
Apr 04 2024	BUY Exercise of conversion of derivative security	$175,174 $9.45 p/Share	18,537 Added 3.74%	477,536 Common Stock
Apr 03 2024	SELL Open market or private sale	$6,805,318 $244.4 p/Share	27,845 Reduced 5.72%	458,999 Common Stock
Apr 03 2024	BUY Exercise of conversion of derivative security	$263,135 $9.45 p/Share	27,845 Added 5.41%	486,844 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	5,786 Added 21.77%	20,787 Common Stock
Jan 16 2024	SELL Payment of exercise price or tax liability	$377,100 $243.92 p/Share	1,546 Reduced 9.34%	15,001 Common Stock
Jan 16 2023	BUY Grant, award, or other acquisition	-	20,001 Added 50.0%	20,001 Common Stock

Rebecca Taub

Pres., R&D, and CMO

West Conshohocken, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MDGL shares.

Notify only if

Value

Insider Trading

Get notified when an Madrigal Pharmaceuticals, Inc. insider buys or sells MDGL shares.

Notify only if

Operation

Value

Type

News

Receive news related to MADRIGAL PHARMACEUTICALS, INC.

Track Activities on MDGL

Account